Drug Profile
Cabergoline
Alternative Names: Cabaser; CG 101; Dostinex; FCE 21336; PNU 142799Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Kissei Pharmaceutical
- Class Antiparkinsonians; Ergolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Galactorrhoea; Hyperprolactinaemia; Parkinson's disease
- Discontinued Breast cancer; Pituitary cancer; Restless legs syndrome
Most Recent Events
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
- 13 Sep 2004 A study has been added to the adverse events and Parkinson's disease therapeutic trials sections
- 27 Aug 2003 A study has been added to the adverse events and Parkinson's disease therapeutic trials sections